JP2022546456A5 - - Google Patents

Info

Publication number
JP2022546456A5
JP2022546456A5 JP2022513372A JP2022513372A JP2022546456A5 JP 2022546456 A5 JP2022546456 A5 JP 2022546456A5 JP 2022513372 A JP2022513372 A JP 2022513372A JP 2022513372 A JP2022513372 A JP 2022513372A JP 2022546456 A5 JP2022546456 A5 JP 2022546456A5
Authority
JP
Japan
Prior art keywords
esketamine
treatment
patient
pharmaceutical composition
suicide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058030 external-priority patent/WO2021038500A2/en
Publication of JP2022546456A publication Critical patent/JP2022546456A/ja
Publication of JP2022546456A5 publication Critical patent/JP2022546456A5/ja
Pending legal-status Critical Current

Links

JP2022513372A 2019-08-28 2020-08-28 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン Pending JP2022546456A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962892841P 2019-08-28 2019-08-28
US62/892,841 2019-08-28
US201962897593P 2019-09-09 2019-09-09
US62/897,593 2019-09-09
PCT/IB2020/058030 WO2021038500A2 (en) 2019-08-28 2020-08-28 Esketamine for the treatment of patients with major depressive disorder, including suicidality

Publications (2)

Publication Number Publication Date
JP2022546456A JP2022546456A (ja) 2022-11-04
JP2022546456A5 true JP2022546456A5 (https=) 2023-09-04

Family

ID=74685267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513372A Pending JP2022546456A (ja) 2019-08-28 2020-08-28 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン

Country Status (5)

Country Link
US (1) US20220304950A1 (https=)
EP (1) EP4021432A4 (https=)
JP (1) JP2022546456A (https=)
CN (1) CN114286674A (https=)
WO (1) WO2021038500A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
AU2022283967A1 (en) * 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
WO2025057111A1 (en) * 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder
WO2025256585A1 (zh) * 2024-06-12 2025-12-18 江苏恩华药业股份有限公司 R-氯胺酮在治疗伴急性自杀意念或行为的抑郁症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
DE10306686A1 (de) 2003-02-12 2004-08-26 Ing. Erich Pfeiffer Gmbh Austragvorrichtung zur manuellen Erzeugung eines Volumenstroms
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
FR3003481B1 (fr) 2013-03-19 2020-05-15 Aptar France Sas Dispositif de distribution de produit fluide.
AU2015318123A1 (en) * 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
KR20240011237A (ko) * 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민

Similar Documents

Publication Publication Date Title
JP2022546456A5 (https=)
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
JP2020002171A5 (https=)
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JP2006513184A5 (https=)
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
JP2018507243A5 (https=)
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
JP2019501886A5 (https=)
JP2021535161A5 (https=)
JP2020504129A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022523530A5 (https=)
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
JP2004537500A5 (https=)
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
JP2008534503A5 (https=)
JP2021532155A5 (https=)
Bourdin et al. MELTEMI and COLUMBA: 5-year comparative safety analysis of benralizumab and mepolizumab
JP2019507786A5 (https=)
MX2024001266A (es) 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
JP2020510011A5 (https=)
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2